Benefit of Bet v 1 contiguous overlapping peptide immunotherapy persists during first follow-up season.
Details
Serval ID
serval:BIB_0DB48862B6C0
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Benefit of Bet v 1 contiguous overlapping peptide immunotherapy persists during first follow-up season.
Journal
The Journal of allergy and clinical immunology
ISSN
1097-6825 (Electronic)
ISSN-L
0091-6749
Publication state
Published
Issued date
08/2018
Peer-reviewed
Oui
Volume
142
Number
2
Pages
678-680.e7
Language
english
Notes
Publication types: Clinical Trial, Phase II ; Letter ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Publication Status: ppublish
Abstract
A short course of 5 injection AIT with Bet v 1 Contiguous Overlapping Peptides was well tolerated and improved allergic rhinitis during the 2 <sup>nd</sup> pollen season after treatment. Long lasting efficacy was associated with a persistent allergen-specific IgG4 response.
Keywords
Administration, Sublingual, Adult, Antigens, Plant/immunology, Antigens, Plant/therapeutic use, Betula/immunology, Desensitization, Immunologic/methods, Europe, Female, Follow-Up Studies, Humans, Hypersensitivity/immunology, Hypersensitivity/therapy, Male, Middle Aged, Peptides/immunology, Peptides/therapeutic use, Pollen/immunology, Quality of Life
Pubmed
Web of science
Create date
26/04/2018 18:46
Last modification date
12/09/2019 6:10